UPDATE 2-Rigel eye drug fails mid-stage study, shares fall

August 13, 2014 2:51 PM

14 0

Aug 13 (Reuters) - Rigel Pharmaceuticals Inc said it would stop testing its drug for some patients with dry eye disease after the treatment failed a mid-stage study.

The study was evaluating the eye drop formulation of the drug, R348, against a placebo. The drug is aimed at reducing the underlying inflammation responsible for the symptoms of chronic dry eye syndrome.

Also read: Apple tells feds ‘new entrants’ to auto industry should get same testing rights as incumbents

Read more

To category page

Loading...